Intensive Studies for Recertification: Critical Care Pharmacy (Cert #L199022)

ACPE Numbers:
0204-9999-18-227-H01-P
0204-0000-18-241-H01-P
0204-0000-18-251-H01-P


Release Date: 02/06/2019
Expiration Date: 08/06/2019
Activity Type: Application-based
CE Credits: 4 hours
Activity Fee: $100 (ASHP member); $150 (non-member) 

Accreditation for Pharmacists

The American Society of Health-System Pharmacistsis accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

These activities were recorded during a live educational event on December 3-4, 2018 at the Midyear Clinical Meeting in Anaheim, California. Learners who claimed credit for the live activities should not claim credit for these home study activities. 

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Clinical Topics/Therapeutics
  • Critical Care
  • Anticoagulation
  • Pharmacogenomics

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in critical care pharmacy. 

The Critical Care Pharmacy Intensive Study  Recertification Package consists of 3 activities (see table below) recorded during a live educational event on December 3-4, 2018 at the Midyear Clinical Meeting in Anaheim, California and provides up to 4 hours of continuing pharmacy education and/or recertification credit.                                                                                                                                                                                  

These activities are part of the ASHP professional development program for BCCCP recertification approved by the BPS. For pharmacists who maintain more than one certification, two of the activities are approved for multiple specialties (see table below). 

Recertification Credit*

Board certified pharmacists are eligible to receive up to 4 hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Participants who pass the assessments between February 6, 2019 - August 6, 2019, will be eligible for recertification credit for 2019.

 

Learning Module

ACPE Number

Credit Hours

Specialty

*Assessment Pass Point

Expanding the Roles of Clinical Pharmacogenomics and Its Implementation*

0204-9999-18-227-H01-P

1.5

BCACP, BCCCP, BCGP, BCPPS, BCPS

71%

Updates in the Management of Pain, Agitation, and Delirium in the ICU

0204-0000-18-241-H01-P

1

BCCCP

66%

Individualizing Anticoagulation in the Acutely Ill: A Case-Based Approach

0204-0000-18-251-H01-P

1.5

BCCCP, BCPS

71%


Learning Objectives

Expanding the Roles of Clinical Pharmacogenomics and Its Implementation*
0204-9999-18-227-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Recommend the key steps in the implementation of pharmacogenetics testing in clinical practice.
  • Evaluate strategies to initiate pharmacogenetic testing at your organization.
  • Given a case study, evaluate key elements of a pharmacogenomics testing product.
  • Given a case study, recommend appropriate pharmacogenomics resources based on specific needs in the implementation process.

This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP), Board Certified Critical Care Pharmacist (BCCCP), Board Certified Geriatric Pharmacist (BCGP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Updates in the Management of Pain, Agitation, and Delirium in the ICU
0204-0000-18-241-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Compare the substantial changes to the 2018 Society of Critical Care Medicine (SCCM) guidelines to the 2013 guidelines and their impact on patient assessment and pharmacotherapy.
  • Given a patient case, discuss the assessment of pain, agitation, and delirium, as well as the evidence-based goals for medication titration in a critically ill patient.
  • Given a patient case, evaluate pharmacotherapy options and sedation strategies for the prevention and management of pain, agitation, and delirium in a critically ill patient.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) recertification credit. 

Individualizing Anticoagulation in the Acutely Ill: A Case-Based Approach
0204-0000-18-251-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Identify unique characteristics of acutely ill patients that influence the approach to anticoagulation.
  • Develop and implement an acute anticoagulation strategy for an acutely ill patient.
  • Given a patient case, design a revised anticoagulation regimen and a follow-up assessment plan for an acutely ill patient.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Faculty

Gillian C. Bell, Pharm.D.
Interim Director, Personalized Medicine
Mission Health
Asheville, North Carolina 

William Dager, Pharm.D., BCPS, FASHP, FCCM, FCCP, MCCM
Pharmacist Specialist
University of California, Davis Medical Center
Sacramento, California 

Jeremy DeGrado, Pharm.D., BCCCP, BCPS
Clinical Pharmacy Specialist, Critical Care
Brigham and Women's Hospital
Boston, Massachusetts 

Henry Dunnenberger, Pharm.D., BCPS
Director, Pharmacogenomics
NorthShore University HealthSystem
Evanston, Illinois 

Michael P. Gulseth, Pharm.D., BCPS, FASHP
Program Director for Anticoagulation Services
Sanford USD Medical Center
Sioux Falls, South Dakota 

Benjamin Hohlfelder, Pharm.D., BCCCP, BCPS
Critical Care Pharmacy Clinical Specialist
Cleveland Clinic
Willoughby, Ohio 

Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Clinical Pharmacy Practice Manager
Brigham and Women's Hospital
Foxboro, Massachusetts 

Content Matter Experts

Christopher Betz, Pharm.D., BCPS, FASHP, FKSHP
Professor, Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Louisville, Kentucky 

Snehal H. Bhatt, Pharm.D., BCPS
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts 

Angela L. Bingham, Pharm.D., BCCCP, BCNSP, BCPS
Associate Professor of Clinical Pharmacy
Philadelphia College of Pharmacy – University of the Sciences
Philadelphia, Pennsylvania
Clinical Pharmacy Specialist
Cooper University Hospital
Camden, New Jersey 

Kelly Epplen, Pharm.D., B.S.Pharm., BCACP, FASHP
Associate Professor of Clinical Pharmacy Practice
The James L. Winkle College of Pharmacy
University of Cincinnati
Cincinnati, Ohio 

Mary Hess, Pharm.D., B.S. Pharm., BCCCP, FASHP, FCCM, FCCP
Associate Dean of Student Affairs
Professor of Pharmacy Practice
Jefferson College of Pharmacy
Philadelphia, Pennsylvania 

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Adjunct Associate
University of Oklahoma - College of Medicine
Oklahoma City, Oklahoma 

Ali Roberts, Pharm.D., BCPS
Medical Science Liaison II
Guardant Health
Redwood City, California 

Maria Shin, Pharm.D., BCGP, BCPS
Assistant Professor
Sullivan University College of Pharmacy
Louisville, Kentucky 

Reviewers

Holly L. Byrnes, Pharm D., BCPS
Susan R. Dombrowski, M.S., R.Ph.
Kristi Hofer, Pharm.D.
Robert Tremmel, Pharm.D., R.Ph. 

Field Testers 

Ahmed Ali, BCPS
Shannon Allcron, Pharm.D., BCCCP, BCPS
Steven Asbill, Pharm.D., BCPS
John Austin, Pharm.D., BCCCP, BCPS
Jennifer Banks, Pharm.D, BCACP, BCGP, BCPS, BC-ADM, CDE
MonicaBogenschutz, Pharm.D, BCPPS, BCPS
Sarah Buranich, Pharm.D., BCCCP
Allorie Caldwell, Pharm.D., BCCCP
Raymond Chow, Pharm.D., BCCCP
Heather Dedman, B.Sc., BCPPS, BSP
Elizabeth ClaireElson, Pharm.D., BCPPS
Nicholas Farina, Pharm.D., BCCCP
Brian Ferullo, Pharm.D., BCGP
Kristie Field, Pharm.D., BCCCP
Jacqueline Finger, Pharm.D., BCCCP
Joe Guidos, Pharm.D., BCCCP, BCPS
Amy Holmes, Pharm.D., BCPPS
Suwen Lim, M.ClinPharm, BCACP, BCGP, BCOP, BCPS
Sana Mandal, Pharm.D. BCPS
Alicia Sacco, Pharm.D., BCCCP
Michael Schontz, Pharm.D., BCCCP, BCPS
Zachary Smith, Pharm.D., BCCCP, BCPS
Conner Sothoron, Pharm.D., BCCCP, BCPS
Colleen Teevan, Pharm.D., BCCCP, BCPS
Peter Ty, Pharm.D., BCCCP, BCPS
Alan Zhao, Pharm.D., BCCCP, BCPS
Juliana Zschoche, Pharm.D., BCPS            

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Henry Dunnenberger
    • Admera Health - Consultant, Honorarium
    • Veritas Genetics - Consultant
  •  Michael P. Gulseth
    • BMS - Advisory Board, Speakers Bureau
    • Janssen - Speakers Bureau
    • Pfizer - Speakers Bureau
    • Portola - Advisory Board, Speakers Bureau
  • All other presenters, program chairs, planners, reviewers, staff, and others with an opportunity to control CE content, have nothing to disclose. 

Methods and CE Requirements

Activities consist of audio/ video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

*This activity was developed in partnership between ASHP and the American Pharmacists Association (APhA).